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A B S T R A C T 
 
This study analyzes a strategy framwork for deciding between alliances 
or acquisition of Johnson & Johnson Pharmeutical Company. The 
general objective of this study is to determine the appropriate 
corporate development strategy of Johnson & Johnson to 
strengthening the position in the area of infectious diseasese to help 
the mankind to get the best anti infectious drugs with the affordable 
price. Infectious diseases is a second leading killer worldwide, it is 
consist of HIV/ AIDS, TB, Hepatitis C, etc. Infectious diseases have 
caused an unprecedented global health crisis. The Asia division of 
Johnson & Johnson plans to invest in open innovation through more 
research partnerships and collaborative efforts that connect the 
medical and academic communities to its R&D centers especially in 
infectious disease. The data used in this research is data result of 
observation, literature study and interviews with senior executives and 
consultants who  handle comparable decision of Johnson&Johnson. 
The data show that alliance is preferrable. High uncertainty within the 
environment is the most influencing factor to determine this choice. 
Due to the industry nature, many R&D collaborations in developing 
particular drugs are established. By defining the proper governance 
structure the collaboration can limit the risk of losing in the learning 
race and core competencies spillover while obtaining the knowledge 
access to the counterparty. The Strategic alliance between Johnson & 
Johnson and Cipla Inc can help them toughen the corporate 
development strategy. Because of their similarities in the production of 
anti-infectious drugs, they can cooperate to penetrate emerging 
markets and do several R&D collaborations to create a competitive 
advantage.  
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Introduction 
A business strategy is an important thing that 
needs to be done from the start. Business 
strategy is the company's efforts to take 
policies and guidelines that have 
commitments and integrated actions and are 
designed to build excellence in business 
competition to meet and achieve business 
goals. In business development, alliances and 
acquisitions are an important technique. 
Since the 1990s the alliance is a technique 
choice that is quite effective in business, 
where each element is able to work together 
in developing a project or business.  
This study focus on a strategy framwork for 
deciding between alliance or acquisition of 
Johnson&Johnson Pharmaceutical Company. 
Johnson&Johnson is the largest 
pharmaceutical company in 2019 according 
to Fortune 500. Based on Johnson&Johnson 
company structure, it has three major 
segments of consumer health care, medical 
devices and diagnostics and pharmaceutical 
which offer the world’s broadest range of 
health care products.  
Johnson&Johnson’s vision is to be a source 
of innovation for emerging markets and 
address the unique needs of Asia Pacific 
patients. Company’s current strategy is 
achieving growth through differentiated 
medicines, transformational pipeline and 
global product launches. Johnson&Johnson 
has also entered into pharmaceutical research 
partnerships that connect biotech, medical, 
and academic communities to its global 
research centers.  
Johnson & Johnson’s pharmaceutical is 
considered to be promising partner especially 
in infectious disease. Infectious disease is a 
disease caused by the entry of germs. This 
disease is transmitted from one person to 
another. The main causes of infection 
include bacteria and living organisms 
(organisms). These germs spread in various 
ways and vectors. Infectious diseases is a 
second leading killer worldwide, it is consist 
of HIV/ AIDS, TB, Hepatitis C, etc 
The Asia division of Johnson & Johnson 
plans to invest in open innovation through 
more research partnerships and collaborative 
efforts that connect the medical and 
academic communities to its R&D centers 
especially in the production of anti infectious 
drugs. Therefore , the best strategic 
partnership of Johnson and Johnson through 
alliance or acquisition because of high fit and 
high synergies. 
Based on the data above, this research will be  
focus to determine and analyze the best 
strategy framwork for deciding  between 
alliance or acquisition of Johnson&Johnson 
Pharmaceutical company with the specific 
case study on strategy farmwork of Johnson 
& Johnson and Cipla Inc in the production 
of anti-infectious drugs. This study is very 
important because with the proper 
collaboration between the two companies it 
can make a major contribution to the world 
of health, especially for infectious diseases, so 
that, patients who are detected by the disease 
can get good anti-infective drugs at affordable 
prices. 
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Literature Review 
The concept of Halal Value Chain 
Alliance 
A company's experience in managing 
acquisitions or alliances is bound to influence 
its choices. Some businesses have developed 
abilities to manage acquisitions or alliances 
over the years and regard them as core 
competencies. They've created special teams 
to act as repositories of knowledge and 
institutionalized processes to identify targets, 
bid or negotiate with them, handle due 
diligence, and tackle issues that arise after a 
deal is made. They've learned the dos and 
don'ts from experience and created templates 
that help executives manage specific 
acquisition- or alliance-related tasks. In 
addition, they've developed formal and 
informal training programs that sharpen 
managers' deal-related skills. (Jeffrey H. 
Dyer.2004) 
Some analysts may say that strategic alliances 
are a recent phenomena in our time, in fact 
collaborations between enterprises are as old 
as the existence of such enterprises. Examples 
would be early credit institutions or trade 
associations like the early Dutch guilds. There 
have always been strategic alliances, but in the 
last couple of decades the focus and reasons 
for strategic alliances has evolved very quickly. 
(Cumming. 2009) 
The success of any alliance depends on how 
effective the capabilities of the involved 
enterprises are matched and whether the full 
commitment of each partner to the alliance is 
achieved. There is no partnership without 
trade-offs, but the benefits of it must 
preponderate the disadvantages, because 
alliances are made to fill gaps in each 
others´capabilities and capacities. Some key 
factors that have to be considered to be able 
to manage a successful alliance include. 
(Margharita,2010)  
 Understanding: The cooperating 
companies need a clear understanding 
of the potential partner´s resources and 
interests and this understanding should 
be the base of set the alliance goals. 
 No time pressure: During negotiations 
time pressure must not have an 
influence on the outcome of the 
process. Managers need time to 
establish a working relationship with 
each other, develop a time plan, set 
milestones, and design communication 
channels. 
 Limited alliances: Some 
incompatibilities between enterprises 
might not be avoidable, so the number 
of alliances should be limited to a 
necessary amount, which enables the 
companies to achieve their goals. 
 Good connection: Negotiations need 
experienced managers. The managers 
from large firms need to be connected 
very well so they have the possibility to 
integrate different departments and 
business areas over internal borders, 
and they need legitimations and 
support from the top management. 
 Creation of trust and goodwill: The 
best basis for a profit-yielding 
cooperation between enterprises is the 
creation of trust and goodwill, because 
it increases tolerance, intensity and 
openness of communication and makes 
the common work easier. Further it 
leads to equal and satisfied partners. 
 Intense relationship: Intensifying the 
partnership leads to the fact that 
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partners get to know each other better, 
each other's interests and operating 
styles and increases trust. 
 
Acquisition 
Corporate acquisitions are a common and a 
popular form of corporate development. 
With an overall yearly value of hundreds of 
billions of dollars and numbering in tens of 
thousands (Cartwright & Schoenberg, 2006) 
acquisitions are also the most important form 
of foreign direct investment (Brackman, 
Garretsen, & van Marrewijk, 2006; 
Schjelderup, 2001), with about 75% of FDI 
being in the form of acquisitions (UNCTAD, 
2000). Even if acquisitions are very common, 
research results on their effect on company 
profitability and performance are mixed, and 
there is no clear wisdom on wealth transfers 
between the acquiring and target company 
shareholders. (Bruner, 2004b; Cartwright et 
al., 2006; Moeller, Schlingemann, & Stultz, 
2005). 
 
Competitive Advantage 
Besides of Alliace and Acquisition, the final 
destination of the company is reaching 
competitive advantage. Competitive 
advantage refers to the comparative positional 
superiority in the marketplace that leads a 
firm to outperform its rivals (Porter, 1985). 
Competitive advantage has been defined in 
many different ways. According to Schendel 
(1978, p.25), competitive advantage is the 
unique position an organisation works hard 
to develop through its competitors. 
Competitive advantage is the ability of an 
organization to create a strong position over 
its competitors” (Li, Ragu-Nathan, Ragu-
Nathan, and Rao, 2006, p.111). 
There are three determinants to create a 
competitive advantage: 
1. Benefit. It is refers to something that the 
customers truly need. It offer real value, 
product's features,  advantages, and the 
benefit for  customers.  
2. Target market. The customer of the 
product , the company should now 
what the customer need  to become 
their life better. That’s how the 
company create demand, the driver of 
all economic growth.  
3. Competition. Identification of real 
competitors. It is include anything else 
the customer could do to meet the need 
we can fulfill. 
 
Method, Data, and Analysis 
This research uses a qualitative method 
approach. The data sources used in this study 
are primary and secondary data.The data 
primer used in this research is observation 
and interviews with senior executives and 
consultants who handle comparable decision 
of Johnson&Johnson. While  the secondary 
data from literature review of Johnson& 
Johnson and Cipla Inc. 
 
Result and Discussion 
Strategic Goals of Johnson & Johnson  for the 
Coming 5 to 10 Years  
We established a SWOT analysis to 
discover opportunities for the upcoming 5 to 10 
years. 
Journal of Digital Marketing And Halal Industry  
Vol. I, No. I (2019), 25-46 
 
 
http://journal.walisongo.ac.id/index.php/JDMHI/index 
http://dx.doi.org/xx.xxxx/jdmhi.2019.xx.xxx 
29 | P a g e  
 
Appendix 1 SWOT Analysis Johnson & Johnson 
Strengths Weaknesses Opportunities Threats 
A Substantial Marketing Arsenal 
Johnson & Johnson can call 
upon a network of subsidiaries 
armed with significant sales and 
marketing prowess, as well as 
expertise in a number of therapy 
areas. The company possesses a 
global sales force which serves to 
attract joint venture possibilities. 
Strategic Acquisitions 
J&J has maintained a stable 
financial position by utilizing cash 
reserves to finance timely corporate 
acquisitions. Its Triple A Credit 
Rating represents that a company 
able to take advantage of 
opportunities that arise without 
being limited by burdensome levels 
of debt. 
 
Product Diversification 
The J&J pharmaceutical portfolio, 
and its large Medical Devices & 
Diagnostics and Consumer Health 
divisions serves to reduce 
dependence upon any one area. 
This diversification allows a wider 
range of choice when pursuing 
opportunities with the greatest 
growth prospects. 
Positive Revenue Growth 
Projections 
The potential of an 
impressive number of new product 
launches and the promise of 
achieving forecast sales lead to an 
increase of revenue growth 
estimation. 
Dependence on the 
Success of Launch 
Products 
Many new 
launch products are 
vulnerable to the 
uncertainty of 
regulatory review and 
ultimate market 
benefits may vary 
substantially from 
forecast, therefore, a 
reliance upon launch 
products potentially 
represents a threat to 
J&J’s outlook. 
Reliance on Small 
Molecular Drugs 
Compared to 
biologics, small 
molecules are notably 
more impacted by 
generic competition. 
As such, although the 
J&J is engaged in 
producing new small 
molecule products, 
when coming off-
patent, declines are 
still forecast. 
Wide Range of Potential 
Cross-selling 
Opportunities 
J&J is in a position 
to strategically develop a 
myriad of cross selling 
opportunities. 
Maximizing its balance 
between Pharmaceuticals, 
Diagnostics, and Medical 
Devices could result in 
increased revenues. 
Potential to Exploit 
Biologics Market 
The additional of further 
biologics to its portfolio 
can serve as a buffer as 
small molecule patents 
expiries. 
 
Further market 
expansion to developing 
countries 
For infectious diseases, 
developing countries still 
need cheap drugs to fulfill 
consumers needs of 
affordable medicine. It is 
a big project to develop 
and potentially could 
broaden it alliance 
network. 
Negative Impact of 
Recent Product 
Recalls 
J&J has the 
misfortune of 
having to recall of 
more than 40 
medicines recently, 
FDA inspectors 
required the 
company to recall 
the children’s 
medications after 
discovering the 
company had not 
looked into dozens 
of consumer 
complaints about 
“black or dark 
specks” in Tylenol 
and other products. 
The company 
stands to take a hit 
to its sterling 
reputation as 
congressional 
lawmakers are 
blasting the 
company’s 
competence and 
integrity. 
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There are two most strategic goals of 
Johnson&Johnson 
1. Strengthening the Position in the Area of 
Infectious Diseases 
Infectious diseases is a second leading killer 
worldwide, it is consist of HIV/ AIDS, TB, 
Hepatitis C, etc. Infectious diseases have 
caused an unprecedented global health crisis, 
accounting for more than 5 million deaths 
each year, with the majority of these in 
developing countries, particularly sub-
Saharan Africa (World Health Organization 
report, 2002).  
The Janssen Pharmaceutical Companies of 
Johnson & Johnson are dedicated to 
addressing and solving the most important 
unmet medical needs of time, including 
infectious disease (e.g. HIV/AIDS, Hepatitis 
C and tuberculosis).  There are many market 
products for infectious disease , such as in the 
appendix below: 
Appendix 2 Infectious Diseases and its 
medicine 
Infectious Diseases Medicines 
HIV/AIDS Prezista, 
Edurant,Intelence, 
Doribex, TMC 278 
Tuberculosis  TMC 207, TMC 407 
Hepatitis C TMC 435, Telepriver 
Malaria, tuberculosis, 
Ebola and HIV 
Crucell vaccines in 
developme 
 
Filings/approvals assumed to be in US and 
EU unless otherwise noted. This information 
is accurate as of the date hereof to the best of 
the Company’s knowledge. Johnson & 
Johnson assumes no obligation to update this 
information (johnson&johnson.2017). 
  The FDA has granted accelerated approval 
for Johnson & Johnson's anti-HIV protease 
inhibitor Prezista (darunavir, previously 
known as TMC114) co-administered with 
ritonavir for use in combination therapy in 
treatment-experienced patients who have 
failed other antiretroviral therapies 
(hospitalpharma, 2010). Prezista is building 
to market leadership because it was approved 
in 101 countries in the world. The tough 
competitor of Prezista is Aptivus from 
Boehringer Ingelheim Pharmaceutical 
company. 
Basically, what makes a product 
differentiation difficult is the fact that both 
drugs have a novel resistance profile that will 
be of great value, and that both have been 
indicated for use in salvage therapy. In 
addition, the two drugs remain difficult to 
compare since they have been tested on 
different patient populations, with trial 
participants having quite different levels of 
treatment experience and resistance profiles.  
However, pricing has been a major concern, 
with Aptivus and Roche and Trimeris' 
Fuzeon (enfuvirtide) - the only currently 
approved entry inhibitor - ranking among the 
top five most expensive HIV drugs on the 
market (hospitalpharma.2010). In contrast, 
The Fair Price Coalition Group, has 
welcomed the low pricing set by Johnson & 
Johnson for Prezista, giving the drug positive 
PR from an unexpected angle and thus 
possibly easing acceptance among HIV 
patients. 
On the other hand, within the 
pharmaceutical industry there are only a 
small number of companies that produce 
quality-assured Tuberculosis drugs, such as 
TMC 207 from Tibotec and the TB 
(Tuberculosis) alliance. TMC207 has been 
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successfully applied in a phase II efficacy 
study because TMC207 has promise for not 
only reducing treatment burden, but also 
providing a powerful tool against TB that is 
resistant to current TB drugs. 
The main problems preventing scale-up of 
Tuberculosis treatment is because for some 
medicines there is only one source for the 
active ingredient needed for drug production.  
There is little commercial interest within the 
pharmaceutical industry to develop and sell 
MDR-TB drugs  because investment in 
research has been widely inadequate due to 
the perception that TB is a poor people’s 
disease. . Therefore, the lack of competition 
among drug makers has led to high drug 
prices, which have made access to multidrug-
resistant tuberculosis (MDR-TB) treatment 
difficult and very costly. 
Moreover, Hepatitis C (HCV) is other 
infectious disease, the successful drugs for the 
disease is Telaprevir (VX-950), marketed as 
the brand name INCIVEX, the world’s 
second-biggest seller of health products. The 
drug for the treatment of hepatitis is co-
developed by Vertex and Johnson & 
Johnson. On May 23rd 2011, US FDA 
approved Telaprevir for the treatment of 
people with chronic genotype 1 hepatitis C 
with compensated liver disease.  
The biggest competitor of Incivex is Victrelis 
from Mercks Pharmaceutical company, also 
known as Boceprevir, which became the first 
hepatitis C drug in almost a decade to win 
FDA approval. Victrelis effectively cured 
more than 60 percent of patients in clinical 
trials when used along with existing drugs. 
Incivex’s drug, along with a competitor from 
Merck, has created new demand for 
treatment among the estimated 3 million 
Americans with hepatitis C infections.  
Incivex becomes the only newly approved 
drug to reach blockbuster sales ($1000 
million) in the first year of marketing and 
Victrelis is projected to have sales of $ 150 
million in 2011 (krishan-maghon, 2011).  
2. Expanding Market to Developing Countries  
Developing countries are prosperous market 
for Johnson&Johnson. For example for Asia. 
This continent has a lot of developing 
countries. In June, 2009, J&J established 
R&D center in Shanghai. The center will 
ensure that Asia becomes a crucial part of its 
portfolio development in all its strategic 
therapeutic areas, include neuroscience, 
cardiovascular and metabolic disease, 
immunology, oncology and virology. A special 
focus will be placed on diseases with specific, 
high unmet needs in the region. These 
include oncology, infectious and metabolic 
diseases. The Asia division plans to invest in 
open innovation through more research 
partnerships and collaborative efforts that 
connect the medical and academic 
communities to its R&D centers. For the 
future 10 years, the expansion strategy is still 
need to developed and improved. In the 
appendix 3 (below) show the journey of 
Johnson and Johnson 
Collaboration/Agreement /Acquires in the 
drugs of  infectious diseases ( AIDS, 
Tuberculosis, Hepatitis C ) from 2002 till 
2018. 
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Appendix 3 Johnson & Johnson Collaboration/Agreement /Acquires In The Drugs of Infectious 
Diseases  (AIDS, Tuberculosis, Hepatitis B and Hepatitis C ) 
Years Collaboration/Agreements/ Acquires Explanation 
2002 Johnson & Johnson acquires Tibotec-
Virco BVBA  
To help address the vast unmet needs of patients 
with HIV/AIDS and other infectious diseases 
such as tuberculosis.  
2004 Johnson & Johnson collaboration in the 
microbicides 
field in 2004, with the International 
Partnership 
for Microbicides (IPM).  
The Program provided IPM 
with a royalty-free license for TMC120 
(dapivirine)to develop, manufacture and 
distribute the compound as a vaginal 
microbicide in resourcepoor countries. 
June 2004 Janssen Pharmaceutica, a Johnson & 
Johnson company signed an agreement 
with Vertex Osaka-based Mitsubishi 
Tanabe Pharma. 
To develop and commercialize INCIVEKTM 
(telaprevir). Vertex has rights to commercialize 
INCIVEK in North America. Tibotec has rights 
to commercialize INCIVEK in Europe, South 
America, Australia, the Middle East and certain 
other countries. The agreement also includes a 
royalty on product sales in Europe and other 
territories outside of North America and the Far 
East.  
April 2007 Johnson & Johnson  signed its first 
license agreement with Aspen 
Pharmacare of South 
Africa to provide PREZISTA® in SSA 
and LDCs at a special access price 
The agreement included 
initial operational terms to register, package and 
distribute the 300 mg formulation 
December 
2008 
Johnson &Johnson  entered into a 
license agreement with Emcure 
Pharmaceuticals Limited of 
India 
To distribute and manufacture darunavir 
formulations in India under local trade name 
Virem 
June 2009  Johnson & Johnson announced a 
landmark collaboration with the Global 
Alliance for TB Drug Development (TB 
Alliance) 
To share expertise and resources in the 
development of TMC207 potentially the first TB 
compound with a new mechanism of action in 
40 years — and to work together in the discovery 
of additional new drugs for TB(Tuberculosis) 
July 2009 Johnson & Johnson entered into a 
license and collaboration agreement with 
Gilead Sciences, Inc 
For the development and commercialization of a 
new, once-daily, FDC containing 
EDURANT™and Gilead’s Truvada® 
(emtricitabine and tenofovir disoproxil 
fumarate). 
August 
2009 
 Johnson and Johnson signed a licensing 
agreement with Aspen for 
The initial terms included the registration and 
distribution of the 100 mg formulation for HIV 
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INTELENCE® (etravirine) in SSA treatment-experienced adult patients at a special 
access price. 
2011 Johnson & Johnson entered into 
agreements with multiple generic 
manufacturers: Emcure 
Pharmaceuticals, Hetero Drugs Limited, 
Matrix Laboratories Limited (a Mylan 
Company), 
Strides Arcolab and Aspen Pharmacare 
to register, manufacture, market and 
distribute a 25 mg 
generic version of rilpivirine, in SSA, 
LDCs and India as a single agent 
medicine and a fixed-dose 
combination (FDC) product with 300 mg 
tenofovir disoproxil fumarate and 300 
mg lamivudine 
Four of these agreements were signed before any 
regulatory approval in the U.S. or 
Europe,allowing generic manufacturers to more 
quickly develop formulations and seek 
regulatory approvals of generic rilpivirine 
2014 Johnson & Johnson acquired Alios 
BioPharma, Inc. 
The company acquired Alios BioPharma, Inc. 
for $1.75 billion. As a result of the purchase, 
Alios was incorporated into the infectious 
diseases therapeutic area of the Janssen 
Pharmaceutical Companies of Johnson & 
Johnson 
2015 Johnson and Johnson announced a 
definitive agreement to acquire Novira 
Therapeutics, Inc. 
A privately held, clinical-stage biopharmaceutical 
company developing novel therapies for curative 
treatment of chronic hepatitis B virus (HBV) 
infection.  The acquisition includes Novira's 
portfolio of novel antivirals, including its lead 
candidate, NVR 3-778. 
2018 Johnson & Jonhson has entered into an 
agreement with Arrowhead 
Pharmaceuticals, Inc 
The cooperation for an exclusive, worldwide 
license to develop and commercialize ARO-
HBV, a Phase 1/2 subcutaneous, ribonucleic 
acid interference (RNAi) therapy candidate 
being investigated for the treatment of chronic 
hepatitis B viral infection. 
 
3. Ally or Acquire? – An Approach to 
Determine the Corporate   Development 
Mode  
Before arrived at the proper corporate 
development mode for those two above 
strategic goals, we need to evaluate J&J key 
resources and capabilities and analyze the 
environment.  
4. Johnson&Johnson‘s Key Resources and 
Core Capabilities  
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As one of the top five largest global 
pharmaceutical companies, J&J has a high 
financial endowment with 8.7 percent profit 
growth of USD 81.58 billion in 2018 with 
net income USD 15.29 billion a 6.71% 
increase from 2017. The pharmaceutical 
business itself generated 45 percent of the 
company’s total revenue with USD $76.5 
billion sales in 2017. With the good financial 
performance, the future operational growth 
will increase as new product contributed to 
growth and core brands delivered solid 
performance. They engage in several big 
partnership projects to develop their alliance 
capabilities. Their social and institutional 
capital is strong since J&J’s broad social 
network of partnership with various 
companies and other institutions which has 
different cultural and structural dimensions. 
Additionally, in 2001, J&J has builded up 
their alliance management with series of trial 
and error. After eight to nine years learning 
experiences, nowadays they have a strong 
alliance management worldwide to 
strengthen their geographic presence.  
5. The Environmental Context  
In order to determine the appropriate 
corporate development mode, the framework 
developed by Hoffman and Schaper Rinkel 
(2001) is implemented: 
 Uncertainty: Pharmaceutical industry 
contains high inherent risk by itself. 
The drug research could take 10 to 15 
years before getting FDA approval 
(ABRC, 2017). According PhRMA 
(2018) only 5 out of 5000 experiments 
made through the final approval stage 
costing on average $1.2 billion each. 
Regulation changes as exemplified by 
just recently approved US health reform 
in 2010 increase the uncertainty. 
Various IPR standard and infringement 
by competitors worsen the uncertainty 
as exemplified by litigation cases faced 
by J&J  with its PREZISTA 
infringement by  generic manufacturer 
namely Lupin and Mylan (J&J, 2011). 
Hence the uncertainty level is 
categorized as high.      
 Urgency: Infectious diseases such as 
Hepatitis C and AIDS are invented in 
1989 and 1981 respectively contains 
much room for growth (Stop-Hepatitis, 
2011). WHO (2018) argued almost one-
third of world’s population is infected 
with TB bacili. More than 65% TB 
infection is concentrated in emerging 
countries, so do with Hepatitis C and 
AIDS. Thus solutions for these 
problems are urgently needed. However 
relatively current approvals of several 
pipelines such as EDURANT and 
INCIVO and TMC435 entered phase 
III clinical trials (J&J Pipeline, 2011) 
ease the urgency. Generally the urgency 
is moderate as some of the growth had 
been capitalized by J&J in terms of 
patent approval. 
 Dispersion of Knowledge: 
Pharmaceutical industry is characterized 
by high R&D activities reaching up to 
$165 billion in 2017,average R&D 
spending moderately increased to 
20.9%.  (Prescouters, 2019). Also, 
infectious disease viruses can be 
resistant to existing drugs (Avert, 2017) 
thus new drugs development never 
stops. As infectious disease is a broad 
area, the dispersion of knowledge level 
itself is abundant since many 
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collaborations are required to cover the 
area.  
 Competition: Competition mainly 
comes from generic manufacturer as 
many counterfeit products and IPR 
infringement appear (J&J, 2018). High 
growth in emerging markets 
agglomerates competition there making 
it highly intense. The health reform in 
US regarding price rebates also tighten 
the competition demanding high 
efficiency of firms. Conclusively the 
competition is high for J&J. 
 Behavioral Uncertainty: R&D is the 
most critical value chain in 
pharmaceutical firm as firms spend 
highly on it. The protection of IPR 
alone is not sufficient, this decreases 
efficiency due to high governance cost 
(Hoffman and Schaper-Rinkel, 2001). 
The expensive drug development 
creates incentive for other to behave 
opportunistically to mitigate the 
expensive R&D cost. 
 Persistence of Economic Synergies: 
Most of the drug development occur in 
very specific area such as J&J and 
Gilead with its FDC combination in 
HIV therapy. The trends in the 
collaboration show short-term, 
complementary and specific orientation 
for the parties involved. Therefore we 
can argue that there is low persistence of 
economic synergy. 
 Resource Endowment & Social capital: 
J&J is one of the largest companies in 
health care business thus their financial 
strength is large. As indicated in the 
appendix, J&J had been doing many 
collaborations with several partners 
even some acquisitions. In an article in 
Bloomberg (2011) analysts argue that 
J&J indeed possess high absorptive 
capacity and “eagle eye” in mapping 
potential drugs in development phase. 
Its long establishment and its broad-
based businesses implicitly says that J&J 
possess high social capital. 
Discussion  
To find out and analyze the implications of 
spiritual intelligence and organizational 
citizenship behavior on employee 
performance, then used path analysis. 
Following are the results of regression analysis 
between variables Based on table 4, the 
regression equation Y1 = 2.005 + 0.503X is 
obtained. This equation means that assuming 
a constant value of 2.005, then if spiritual 
intelligence (X) increases one unit, then 
organizational citizenship behavior (Y1) will 
increase by 0.503 or it can be said that 
organizational citizenship behavior will 
change by 0.503 every one unit of spiritual 
intelligence. 
Recommendation: Main Focus on Alliances  
Based on the analysis above we arrive to 
conclusion that alliance is preferrable. High 
uncertainty within the environment perhaps 
is the most influencing factor to determine 
this choice. Also, quite high level of urgency 
to tap in external growth require quicker 
mode of entry to the focus area which prefer 
alliance over acquisitions (Hoffman and 
Schlosser, 2000). Due to its commitment to 
be a broad-based healthcare business J&J 
needs to be present by forming alliances. 
However, high knowledge dispersion level 
exist thus it is impossible to acquire firms in 
all area. Grant and Baden Fuller (2004) stated 
that alliances fit better in situation of broad 
knowledge types and specialization by 
different firms in different areas. The 
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efficiency aspects pointsthat most 
collaborations occurr on very specific area 
and intention to opportunistic behavior  is 
salient in the industry. Lastly as J&J has high 
social capital due to its long existence, 
alliance is preferred. Although J&J is high in 
financial capital and high level of 
competition exists in the industry, alliances 
are the best mode of development 
considering other aspects in the framework, 
especially due to very high level of 
uncertainty. 
As there is urgency to penetrate the emerging 
market where uncertainty is even higher and 
knowledge of particular market is still 
relatively low, less riskier mode of entry is 
more proper. The issue of low IPR in 
emerging market remains issue to solve. The 
entrance to emerging market which 
necessitates sequential synergy i.e distribution 
or manufacturing of products narrow the 
scope of activities to be cooperated. Therefore 
alliance type that protect the property-based 
knowledge in emerging market is favorable. 
“To serve unmet  critical medical needs” is 
the slogan of J&J. This implies that new 
drugs development is occurring on 
continuing basis. Due to the industry nature, 
many R&D collaborations in developing 
particular drugs are established. By defining 
the proper governance structure the 
collaboration can limit the risk of losing in 
the learning race and core competencies 
spillover while obtaining the knowledge 
access to the counterparty.  
 
Partner Search – Implications from 
Johnson&Johnson’s Resource Gaps and Needs  
After identifying alliance as the appropriate 
mode for J&J to attain corporate goals, the 
next step is looking for appropriate partner. 
For this report, we try to develop the alliance 
based on the two goals with the main focus 
on expanding market to developing 
countries. The current situation of entering 
pharmaceutical research partnership gives a 
comprehensive explanation of resources and 
capabilities J&J looks for from potential 
alliance partners. 
1. Potential Alliance Partners – Looking for 
the Fit  
To tap the opportunities existed, J&J should 
pick the appropriate partner. We screen three 
potential partners and reach to Cipla Limited 
as the most potential partners such as in the 
appendix 4. 
 
Appendix 4 Partner Screening 
Company Strategic Fit Market Fit Organization Fit Cultural Fit 
Gilead Rapidly expanding product 
portfolio, growing pipeline of 
investigational drugs and 
approximately 4,200 
employees in offices across 
four continents. 
developing 
ground-breaking 
therapeutics to 
treat life-
threatening 
diseases. 
The structure 
was designed to 
support the 
anticipated 
growth of the 
company and its 
marketed 
products 
High level of 
corporate 
responsibility 
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Cipla Limited offers services like consulting, 
commissioning, engineering, 
project appraisal, quality 
control, know-how transfer, 
support, and plant supply. 
 
Price reduction ability since 
the focus is making a drugs 
for low-level income society. 
 
Pioneered a three-in-one 
tablet called Triomune 
containing a fixed-dose 
combination (FDC) of three 
ARVs (Lamivudine, 
stavudine and Nevirapine 
and also Duovir-N. (contains 
Lamivudine, Zidovudine and 
Nevirapine).  
 
Manufactures generic 
versions of many of the most 
commonly prescribed anti-
retroviral medication in the 
market and is a highly 
capable manufacturer in its 
own right.  
manufacturing 
low-cost anti-
AIDS drugs for 
HIV-positive 
patients in 
developing 
countries makes 
drugs to treat 
cardiovascular 
disease, arthritis, 
diabetes, weight 
control, 
depression and 
many other 
health 
conditions, and 
its products are 
distributed in 
more than 180 
countries 
worldwide 
The structure 
was designed to  
contribute to 
fair and 
transparent 
working 
environment 
All directors 
and senior 
management 
employees 
shall deal on 
behalf of the 
Company with 
professionalis
m, honesty, 
integrity as 
well as high 
moral and 
ethical 
standards.  
Roche focus on developing 
medicines and diagnostics 
that will help patients live 
longer, better lives. 
strive to address 
unmet medical 
needs through 
excellence in 
science – from 
early detection 
and prevention 
of diseases to 
diagnosis, 
treatment and 
treatment 
monitoring. 
Big and well 
established 
company with a 
mature 
organizational 
structure.  
 
The culture 
tends to boost 
the learning 
behavior of 
employees 
from any 
incidents 
happen. 
 
Analysis of Cipla as follows: 
Strategic Focus : High Fit 
 Customer 
 
 
Cipla company produce Daruvir (darunavir 
ethanolate tablets) and Nutrimune 
(antioxidant tablets). Those medicine are 
supportive therapy for HIV/AIDS, thus fit 
with Johnson & Johnson’s concern and 
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might be attractive for Johnson & Johnson. 
Based on annual report, on 2017-2018, Cipla 
exports to more than 170 countries 
worldwide and operates through low-risk, 
low-cost partnership arrangements. The large 
number of products in the registration 
pipeline will aid in increasing the Company’s 
market share. ( Appendix : Cipla growth in 
fixed assets) 
 Competitors 
Cipla has proposed to supply triple 
combination therapy for HIV/AIDS for $350 
per patient per year to Medicins San 
Frontieres. It has also offered to sell the 
therapy for $600 per patient per year to poor 
governments, on the condition that the 
recipient governments provide the drugs for 
free to those with HIV/AIDS and since 
making the initial offer, it has dropped the 
price for some poor governments (cptech, 
2011). Besides, Cipla’s have strong 
competitors who also offered lower prices on 
generic medicine for AIDS which are 
Hetero and Ranbaxy (other Indian generic 
competitors). 
 Cost Structure  
Cipla will continue its Research & 
Development division as future plan of action 
(Appendix: Research Deelopment in Cipla). Due 
the pharmaceutical industry is characterized by 
heavy R&D expenditure, thus Cipla needs 
partner with strong financial resources which will 
matched with Johnson & Johnson for partners 
engaged in Research and Development. 
 Capabilities 
Cipla has core capabilities in production of 
anti-asthma, anti-HIV/AIDS and anti-cancer 
compounds which is fit with Johnson & 
Johnson aim in developing infectious disease 
division. 
Corporate Vision : High Fit 
Cipla’s vision focuses on provide the health 
care infrastructure in developing countries, 
particularly Africa, the price of even the 
cheapest HIV/AIDS drug is still beyond the 
reach of the majority. Basic medical facilities 
and infrastructure are not available.  
“We are aware that we have our own 
limitations and there is only so much that 
one company can do. We are glad that our 
humanitarian gesture on the price front has 
dramatically led to many companies, both 
Indian and international, offering anti-AIDS 
drugs at reduced prices.” Said Dr Y K 
Hamied (Chairman and Managing Director). 
Due to Cipla and Johnson & Johnson have 
same purpose in vision related with 
HIV/AIDS issue, both of Cipla and Johnson 
& Johnson have high fit in corporate vision. 
Corporate Culture: High Fit 
Cipla’s corporate culture is bring health and 
care for people, thus innovation is key for 
create value such as creativity, resource 
(internal and external), employee, and ethical. 
Besides, in Johnson & Johnson also have 
similar corporate culture that also want to 
bring health to people who needed and 
Johnson & Johnson is a company who have 
big concern in innovation. In summary, Cipla 
and Johnson & Johnson have high fit in 
corporate culture, thus those similarity will 
reduce conflict and gap between them. 
Organizational Task Needs : Low Fit 
Cipla faces challenge in patent because patent 
in pharmaceutical industry is still become 
problem in India because lack of awareness 
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from governments in India. This is very 
different from what happened in Johnson & 
Johnson who have high awareness for patent. 
In addition, India is under pressure to change 
its current patent laws to suit only 
multinational companies. Cipla and other 
like minded organisations are fighting this as 
best as possible (annual report of Cipla, 
2018). 
Cipla – Is It the Best Choice?  
Cipla is now a big pharmaceutical company 
in India. Based on Pharmaceutical.com 
(2017), it is in the fourth ranks of the top five 
pharmaceutical company in India with its 
international sales at Rs. 47,319 crore during 
2017. The company made a low-cost anti 
AIDS drugs and also other medicine 
including for TB and Hepatitis for developing 
countries patients. Roughly 40 percent of 
HIV/AIDS patients undergoing antiretroviral 
therapy worldwide take Cipla drugs. 
Considering the established criteria, Cipla 
can helps J&J to achieve its goals. 
Establishing and Managing the Alliance - The 
Appropriate Governance Structure  
Common Objective  
Alliances often ends up in a learning race 
among involved parties (Lei and Slocum, 
1992). The intention to exploit the 
counterparties complementary assets 
maximally creates incentive to behave 
opportunistically within an alliance 
(Harrigan, 1985). Therefore, clear governance 
structure should be established to ensure the 
smoothness of the alliances with the basis of 
framework developed by Das and Teng 
(2000). The first step to do is to establish 
alliance specific goals and the governance 
structure in order to result in a win-win 
solution for both parties. Below are the 
proposed goals and proper structure of 
Johnson & Johnson and Cipla alliance: 
1. To develop an Single Tablet Regimen 
(STR) for AIDS 
AIDS therapy involves the patient to 
consume combination of drugs  (Avert, 
2011). The current trend of Fixed Dose 
Combination (FDC) and Single Tablet 
Regimen (STR) which meld multiple drugs 
into 1 tablet is preferrable as it is more 
effective in suppressing the  HIVvirus 
(Bangsberg et al, 2011). The current strong 
pipelines such as PREZISTA can be exploited 
heavily and combined with other medicine 
co-developed by Cipla to result in another 
STR after EDURANT-TRUVADA STR 
development with Gilead. Developing STR 
involves knowledge based propoerties from 
each firm. According to Das and Teng 
(2000), the best type of alliance in this 
condition is forming bilateral contract in 
form of partnership. Both parties could gain 
access to the technology of each firm in AIDS 
field and exchange information to reach this 
goal. High resource endowment of Johnson 
and Johnson can also help the collaboration 
to be successful as R&D activities only 
occuring cash outflows. 
2. To strengthen the company’s position 
in the area of Hepatitis C & TB 
The status of TMC 207 which is nearly 
approved by FDA and current approval of 
Telaprevir strengthen the portfolio of 
Johnson and Johnson. Cipla as the leader of 
pharmaceuticals company in India can give 
broader knowledge as they are also expert in 
Hepatitis-C and TB. Along with the high 
vision fit particularly in this area, R&D 
collaboration to develop new Hepatitis-C 
especially for other genotypes is highly 
awaited. As both firms have high knowledge 
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resource in the field of Hepatitis C and TB, 
the strength of both firm can be combined 
such as joint R&D and share of facility. In 
this kind knowledge ft. knowledge alliances 
again bilateral contract is preferrable 
according to Das and Teng (2000) framework 
since knowledge spillover can be prevented by 
the proper formulation in the contract. Also 
the low protection of IPR in India exacerbate 
the risk of knowledge spillover. 
3. To penetrate the emerging market 
Johnson & Johnson continued the strong 
progress in emerging markets by sales growing 
14% operationally in Brazil, Russia, India 
and China (Johnson & Johnson’ hand book, 
2010). Thus emerging market offers big 
opportunities to be exploited. However, there 
is high risk incorporating international 
expansion if conducted alone. In order to 
smoothen the process Johnson and Johnson 
can cooperate with Cipla to help them 
penetrate emerging market such as India, 
where Cipla is one the among the industry 
leaders. According to Verbeke (2009) 
Alliance with local partner reduce greatly the 
“distance” and liability of foreignness 
especially process of obtaining local 
knowledge. Cipla expertise in low cost 
manufacturing helps Johnson and Johnson to 
achieve greater efficiency to answer the 
demand in emerging market and mission to 
make AIDS drugs more affordable. The 
property based owned by Johnson and 
Johnson and the local knowledge of Cipla 
according to Das and Teng (2000) will be best 
to form equity joint venture. Johnson and 
Johnson will be at advantage position since 
the knowledge property owned by Cipla is 
more vulnerable to opportunistic behavior 
(Das and Teng, 2000). Reciprocal 
relationship occur here since Cipla also can 
advantage by J&J strong financial strength. 
Alliance Structure 
The alliance's governance structure is 
detrimental to the alliance successfulness 
(Williamson, 1985; Li et al, 2008; Hennart, 
1988). Moreover, Hamel (1991) argued that 
collaboration involving knowledge-based 
properties most likely raises learning race. 
Therefore a clear governance structure should 
be established within the alliance to minimize 
learning race and knowledge spillover. The 
framework by Das and Teng (2000) can help 
firms to carry out the proper governance 
structure for the alliance.  
The joint R&D activity to develop new STR 
drugs for AIDS involves extensive exchange 
of knowledge among both firms. Hence, each 
firm within the alliance contributes their 
knowledge-based resources. According to Das 
and Teng (2000) when both parties within 
the alliance possess knowledge-based 
resource, the proper structure is bilateral 
contract agreements. The agreement will 
determine the role such as who is in charge 
for formulation, manufacturing, registration 
and commercialization of the product and 
the detailed rights and obligation each party 
bears.  
Johnson&Johnson and Cipla would like to 
strengthen its foothold in AIDS sector. 
Therefore they need to exchange knowledge 
relevant to the sector. Johnson and Johnson 
needs Cipla local Indian network to be able 
to penetrate the Indian market to develop 
location-bound Firm Specific Advantage to 
reduce liability of foreignness (Verbeke, 
2009). Simultaneously, Cipla would like to 
strengthen their capabilities in the firm 
market internationalisation and best practices 
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in pharmaceutical industry. The specific 
knowledge possessed by both parties are form 
of knowledge-based resources hence the 
appropriate alliance structure is bilateral 
contract agreements (Das and Teng, 2000). 
The process of knowledge exchange might 
take form as reciprocal personnel training by 
each firm in accordance with the contracts 
established. The personnel exchange within 
both parties is also an important element. 
Delegation of one firm would be involved in 
particular activities relevant to the respective 
agreement in the counterparty firm. Hence 
the transfer of knowledge runs smooth with 
proper scope as determined in the contract.   
Potential Conflicts and Additional 
Considerations  
Defining expected conflicts can help Johnson 
and Johnson anticipate potential conflict to 
occur at later stage. Later conflict resolution 
would be very costly as things will be more 
complicated. Cultural differences, 
opportunistic behavior and unclear roles 
problems within the alliance as will be 
elaborated below. 
Firstly, Although both firms possess similar 
corporate culture, the management styles and 
employees culture may be different as the 
CEO and almost all employees of Cipla is 
Indian. However, cultural differences is 
expected to exist in any alliances. The process 
to create alliance culture which accommodate 
both parties is crucial to be developed. With 
both Johnson & Johnson and Cipla high 
social capital as it has been experienced in 
forming alliance can help to play-off the 
cultural difference.  
Secondly, opportunistic behavior may also 
arise in both parties. High knowledge-based 
resources owned by both parties are  very 
vulnerable as low level of IPR protection in 
India provides more incentive to behave 
opportunistically. This is especially a 
diasadvantage for Johnson and Johnson as 
thay can be categorized more superior than 
Cipla in terms of knowledge based. Thus this 
issue should be addressed comprehensively. 
Lastly, unclear role problem within the 
alliance should be concerned since the it will 
lead to confusion of direction and champion 
within alliance. The structure of alliance 
should be defined clearly and communicated 
towards the personnels who is involved in 
alliance immediately as the alliance is started. 
Governance Model and Decision Making 
Approach  
Alliance often ends in disastrous result as 
Peter (2011) indicated that up to70% 
alliances do not work. Therefore alliance 
mechanism should be established in order to 
ensure the successfulness of an alliance.  
Several things can be done suchs as: 
 Establishing dedicated alliance team. 
The dedicated team is responsible to 
monitor and smoothen the alliance 
process. As stated by Kale et al (2002), 
firms with dedicated alliance team are 
mosre successful with the alliance. This 
also responds to the need of clear role 
and structure to the alliance. This team 
can also act as the culture assimilator so 
to minimize cultural differences. 
 Limiting alliance scope. Li et al (2008) 
said that determining alliance scope can 
enhance the safeguards between 
alliance. As knowledge-based property is 
very vulnerable to opportunistic 
behavior, this step is extremely 
important to avoid excessive knowledge 
spillover. This activity is indirectly 
served by goal establishment to focus in 
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R&D collaboration of particular 
product and in management expertise 
of Cipla.  
 Developing milestones for alliance. The 
alliance would be going for quite long 
time. Therefore a monitoring device is 
needed. Developing milestones with an 
agreed upon parameter could be a way 
to monitor the progress of the alliance. 
Performance of strategic alliances can be 
measured using product developments 
evaluation (Deeds& Hill, 1996). This is 
particularly relevant for the goal number 
one where the collaboration is about 
developing a product. Targeting the 
progress i.e the time to go through 
phase I, II or III can be a way to evaluate 
the successfulness or the progress of the 
alliance. For the goal number two, the 
measurement tool could be how many 
contacts have emerged from the 
collaboration or to compare the 
efficiency level of Johnson&Johnson 
with Cipla. Any deviation from target 
should be considered carefully by the 
dedicated alliance team. Corrective 
action should be take in response to the 
deviation to ensure the smoothnes of 
the alliance performance. By making 
safeguards mentioned above, the 
alliance between Johnson & Johnson 
and Cipla is expected to run smoothly 
since expected conflicts have been 
anticipated. 
Johnson&Johnson’s Alliance Development: 
Creating Competitive Advantage 
Alliance provide a way for organizations to 
leverage resources and a smart way to grow 
(Sari, 2003). Alliance enable business to gain 
competitive advantage through access to a 
partner's resources, including markets, 
technologies, capital and people. 
Furthermore Kotelnikov (2001) stated that 
fast-growing companies rely heavily on 
alliances to extend their operational and 
technical resources. They use alliances to 
benefit from more-established channels of 
distribution, marketing, or brands reputation 
of bigger, better-known players.  
Some reasons may be found to explain how 
the development of an alliance can create a 
competitive advantage. Sari (2003) stated that 
definite reasons attribute to this 
phenomenon are the financial pressures and 
the time constraints that have squeezed 
managers without the resources to fill the 
gaps through internal development. This 
phase can show manager’s ability in dealing 
with changes and solving problems. In 
addition, the development of alliance should 
be in tune to maintain flexibility, core 
competence and the incentives that arise 
from autonomy, while utilizing 
complementary resources for both efficiency 
and learning (Freeman & Perez: 1989). In 
J&J, previous alliances success could be the 
best “teacher” to create a better way to 
develop their alliance with Cipla. To gain the 
market segment access, as stated on their 
alliance objective, the management of the 
alliance should build a strong tool in 
communication, control, and measurement 
system. With an integrated system covering 
those all, the alliance can develop in a proper 
way. 
The Strategic alliance between Johnson & 
Johnson and Cipla Pharmaceutical company 
can help them toughen the corporate 
development strategy. Because of their 
similarities in the production of anti-
infectious drugs, they can cooperate to 
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penetrate emerging markets and do several 
R&D collaborations to develop new 
Hepatitis-C especially for other genotypes. As 
both firms have high knowledge resource in 
the field of Hepatitis C and TB, strengths of 
both firm can be combined such as joint 
R&D (which J&J strength in the financial 
and Cipla in the R&D) and  share their 
facilities. Additionaly Cipla helps J&J answers 
the demand in emerging market to make 
AIDS drugs more affordable. This can result 
in a strengthen competitive position for both 
partners. Therefore, strategic partnership 
between Johnson & Jodnson and Cipla may 
overcome obstacles, for example the 
entrenched competition, hostile government 
regulations, and also cultural customs. 
Conclusion and Sugestion  
Johnson & Johnson is an American 
multinational medical devices, 
pharmaceutical and consumer packaged 
goods manufacturing company. Its common 
stock is a component of the Dow Jones 
Industrial Average and the company is 
ranked No. 37 on the 2018 Fortune 500 list 
of the largest United States corporations by 
total revenue. The company's major 
franchises in the Pharmaceutical segment 
include Immunology, Neuroscience, 
Infectious Disease, and Oncology. Infectious 
diseases have caused an unprecedented global 
health crisis, Infectious diseases products 
include Incivio (telaprevir), a hepatitis C 
protease inhibitor; Intelence (Etravirine), a 
non-nucleoside HIV polymerase inhibitor; 
and Prezista (darunavir), an HIV protease 
inhibitor. Etravirine and darunavir are 
notable for their high barriers to resistance 
development. 
For the future 10 years, the expansion 
strategy is still need to developed and 
improved. Developing countries are 
prosperous market for Johnson&Johnson. 
Especially in  Asia. Asia becomes a crucial 
part of its portfolio development in infectious 
and metabolic diseases. Therefore, open 
innovation through more research 
partnerships and collaborative efforts that 
connect the medical and academic 
communities to its R&D centers is needed by 
Johnson&Johnson. Based on data in the 
research analysis, Cipla is the best choice for 
Johnson&Johnson Alliance because Cipla 
made a low-cost anti AIDS drugs and also 
other medicine including for TB and 
Hepatitis for developing countries patients. 
Roughly 40 percent of HIV/AIDS patients 
undergoing antiretroviral therapy worldwide 
take Cipla drugs. In the established criteria, 
Cipla can helps Johnson&Johnson to achieve 
its goals. 
The joint R&D activity between 
Johnson&Johnson and Cipla Inc to develop 
new STR drugs for AIDS involves extensive 
exchange of knowledge among both firms. 
Each firm within the alliance contributes 
their knowledge-based resources, the proper 
structure is bilateral contract agreements. The 
agreement will determine the role such as 
who is in charge for formulation, 
manufacturing, registration and 
commercialization of the product and the 
detailed rights and obligation each party 
bears. Johnson & Johnson and Cipla would 
like to strengthen its foothold in AIDS sector. 
Therefore they need to exchange knowledge 
relevant to the sector. Johnson & Johnson 
needs Cipla local Indian network to be able 
to penetrate the Indian market to develop 
location-bound Firm Specific Advantage to 
reduce liability of foreignness (Verbeke, 
Journal of Digital Marketing And Halal Industry  
Vol. I, No. I (2019), 25-46 
 
 
http://journal.walisongo.ac.id/index.php/JDMHI/index 
http://dx.doi.org/xx.xxxx/jdmhi.2019.xx.xxx 
44 | P a g e  
 
2009). Cipla expertise in low cost 
manufacturing helps Johnson and Johnson to 
achieve greater efficiency to answer the 
demand in emerging market and mission to 
make AIDS drugs more affordable. 
Furthermore, Cipla would like to strengthen 
their capabilities in the firm market 
internationalisation and best practices in 
pharmaceutical industry. The Strategic 
alliance between Johnson & Johnson and 
Cipla Inc can help them toughen the 
corporate development strategy. Because of 
their similarities in the production of anti-
infectious drugs, they can cooperate to 
penetrate emerging markets and do several 
R&D collaborations to create a competitive 
advantage especially in Asia market to help 
mankind to get the best medicine (anti 
infectious drugs) with affordable prices. In 
the future, we hope Johnson & Johnson can 
develop cooperation with Cipla and other 
companies not only in anti-infectious drugs 
but also in other treatments so that they can 
make the best contribution to the world. 
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